TA ANN HOLDINGS BERHAD (Incorporated in Malaysia)

Condensed consolidated statement of financial position

As at 30 September 2022 - unaudited

	Note	30 September 2022 RM'000	31 December 2021
Assets			RM'000
Property, plant and equipment		729,176	734,102
Right-of-use assets		193,628	197,165
Bearer plants		533,846	519,918
Biological assets		125,936	124,960
Investment in associates		286,031	266,878
Deferred tax assets		26,980	27,054
Goodwill		79,665	79,665
Other intangible assets		6,596	7,200
Total non-current assets		1,981,858	1,956,942
Inventories		140,549	131,223
Biological assets		147,489	129,942
Trade and other receivables	14	50,068	67,468
Current tax assets		49	199
Other investment	23	1,061	1,050
Cash and cash equivalents		599,939	454,945
Total current assets		939,155	784,827
Total assets		2,921,013	2,741,769
Financed by:			
Capital and reserves			
Share capital		444,844	444,844
Treasury shares		(10,417)	(10,417)
Foreign exchange translation reserve		12,350	12,399
Retained earnings		1,332,890	1,166,894
Total equity attributable to owners of the Company		1,779,667	1,613,720
Non-controlling interests		213,842	162,750
Total equity		1,993,509	1,776,470
Liabilities			
Deferred tax liabilities		246,848	217,510
Deferred income		24,152	26,049
Borrowings	27	97,704	147,094
Employee benefits		41,715	37,951
Lease liabilities		1,850	1,933
Total non-current liabilities		412,269	430,537
Trade and other payables		234,202	251,361
Lease liabilities		8,089	8,012
Deferred income		2,439	2,446
Borrowings	27	207,530	231,058
Employee benefits		2,607	3,667
Current tax liabilities		60,368	38,218
Total current liabilities		515,235	534,762
Total liabilities		927,504	965,299
Total equity and liabilities		2,921,013	2,741,769
Net assets per share (RM)		4.00	3.63

The unaudited condensed consolidated statement of financial position should be read in conjunction with the audited financial statements for the year ended 31 December 2021 and the accompanying explanatory notes attached to the interim financial statements.

TA ANN HOLDINGS BERHAD (Incorporated in Malaysia)

Condensed consolidated statement of profit or loss and other comprehensive income

For the period ended 30 September 2022 - unaudited

	Note	Individual Quarter		Cumulativ	e Quarter
		Current Year Quarter Ended 30 September 2022 RM'000	Preceding Year Corresponding Quarter Ended 30 September 2021 RM'000	Current Year to date 30 September 2022 RM'000	Preceding Year Corresponding Period Ended 30 September 2021 RM'000
Revenue	9	594,886	486,857	1,736,793	1,282,822
Cost of sales		(403,407)	(331,942)	(1,180,363)	(927,169)
Gross profit		191,479	154,915	556,430	355,653
Finance income		2,139	1,012	4,976	2,792
Other operating income		5,175	2,934	14,451	9,423
Unrealised (loss) /gain in foreign exchange		-	(10)	-	83
Distribution costs		(29,716)	(29,583)	(113,707)	(77,210)
Administrative expenses		(11,005)	(11,691)	(32,536)	(32,970)
Other expenses		(2,003)	(1,971)	(4,762)	(5,028)
Profit from operations		156,069	115,606	424,852	252,743
Finance costs		(2,853)	(3,244)	(8,643)	(10,370)
Share of profit of equity-accounted investee, net of tax		7,746	13,631	35,028	35,123
Profit before tax	9	160,962	125,993	451,237	277,496
Tax expense	21	(38,438)	(26,118)	(101,721)	(60,096)
Profit after tax		122,524	99,875	349,516	217,400
Change in fair value of biological assets		5,200	26,090	13,433	46,798
Profit after change in fair value of biological assets		127,724	125,965	362,949	264,198
Other comprehensive income, net of tax Item that is or may be reclassified subsequently to profit or loss Foreign exchange translation differences for foreign operations		(310)	(2,510)	(49)	(2,030)
Other comprehensive income for the period, net of tax		(310)	(2,510)	(49)	(2,030)
Total comprehensive income for the period		127,414	123,455	362,900	262,168
Profit attributable to:					
Owners of the Company		101,495	103,293	298,134	218,405
Non-controlling interests		26,229	22,672	64,815	45,793
Profit after change in fair value of biological assets		127,724	125,965	362,949	264,198
Total comprehensive income attributable to: Owners of the Company Non-controlling interests		101,185 26,229	100,783 22,672	298,085 64,815	216,375 45,793
Total comprehensive income for the period		127,414	123,455	362,900	262,168
Earnings per share attributable to owners of the Company :					
Basic/Diluted earnings per ordinary share (sen)	31	23.04	23.45	67.69	49.59

The unaudited condensed consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the audited financial statements for the year ended 31 December 2021 and the accompanying explanatory notes attached to the interim financial statements.

TA ANN HOLDINGS BERHAD (Incorporated in Malaysia)

Condensed consolidated statement of changes in equity For the period ended 30 September 2022 - unaudited

			ers of the Co	mpany			
	Share capital RM'000	n-distributabl Treasury shares RM'000	Foreign	Distributable Retained earnings RM'000	Total RM'000	Non- controlling interests RM'000	Total equity RM'000
At 1 January 2022	444,844	(10,417)	12,399	1,166,894	1,613,720	162,750	1,776,470
Foreign exchange translation differences	-	-	(49)	-	(49)	-	(49)
Total other comprehensive income for the period	-	-	(49)	-	(49)	-	(49)
Profit after change in fair value of biological assets	-	-	-	298,134	298,134	64,815	362,949
Total comprehensive income for the period	-	-	(49)	298,134	298,085	64,815	362,900
Contributions by and distributions to owners of the Company							
- Dividends to owners of the Company	-	-	-	(132,138)	(132,138)	-	(132,138)
- Dividends to non-controlling interests	-	-	-	-	-	(15,176)	(15,176)
Total transactions with owners of the Company	-	-	-	(132,138)	(132,138)	(15,176)	(147,314)
Subscription of shares by non-controlling interests	-	-	-	-	-	1,453	1,453
At 30 September 2022	444,844	(10,417)	12,350	1,332,890	1,779,667	213,842	1,993,509
At 1 January 2021	444,844	(10,417)	14,098	998,035	1,446,560	117,998	1,564,558
Foreign exchange translation differences	-	-	(2,030)	-	(2,030)	-	(2,030)
Total other comprehensive income for the period	-	-	(2,030)	-	(2,030)	-	(2,030)
Profit after change in fair value of biological assets	-	-	-	218,405	218,405	45,793	264,198
Total comprehensive income for the period	-	-	(2,030)	218,405	216,375	45,793	262,168
Contributions by and distributions to owners of the Company							
- Dividends to owners of the Company	-	-	-	(66,069)	(66,069)	-	(66,069)
- Dividends to non-controlling interests	-	-	-	-	-	(2,600)	(2,600)
Total transactions with owners of the Company	-	-	-	(66,069)	(66,069)	(2,600)	(68,669)
Changes in ownership of interests in subsidiaries	-	-	-	116	116	(216)	(100)
At 30 September 2021	444,844	(10,417)	12,068	1,150,487	1,596,982	160,975	1,757,957

The unaudited condensed consolidated statement of changes in equity should be read in conjunction with the audited financial statements for the year ended 31 December 2021 and the accompanying explanatory notes attached to the interim financial statements.

TA ANN HOLDINGS BERHAD (Incorporated in Malaysia)

Condensed consolidated statement of cash flows For the period ended 30 September 2022 - unaudited

Cash flows from operating activities ECA voice Chain voice voice voice voice voice voi	Tor the period children by September 2022 annualica	1 January 2022 to 30 September 2022 RM'000	1 January 2021 to 30 September 2021 RM'000
Profit before tax 451,237 277,496 Adjustment for: 20.076 19,086 Depletion of biological assets 2,295 2,459 Amortisation of biological assets 36,578 35,698 Depreciation of right-of-us assets 36,578 35,698 Depreciation of right-of-us assets 36,578 33,30 Deferred income recognised as income (1,862) (1,900) Finance income (4,976) (2,792) Gain on disposal of property, plant and equipment (204) (1,135) Gain on disposal of property, plant and equipment (3,457) 3508 Share of profit of equity-accounted investee, net of tax (3,5028) (3,123) Operating profit before changes in working capital 483,508 314,038 Changes in working capital (4,866) (5,694) Incorne tax paid (5,377) (1,200) Incoresting activities 430,366 330,202 Changes in working capital (4,866) (5,694) Incorest paid (5,377) (1,206) Net cash from operating activities	Cash flows from operating activities		
Adjurnments for: 19.086 Amortisation of barer plants 2.095 2.459 Amortisation of their intangible assets 356 2.688 Depreciation of property plant and equipment 36.578 33.698 Depreciation of property plant and equipment 36.578 33.695 Depreciation of property plant and equipment (1.862) (1.900) Finance income (1.822) (1.900) Finance income (2.0476) (2.792) Gain on disposal of property, plant and equipment (2.04) (1.133) Gain on disposal of property investments (1.250) - Property, plant and equipment written off 351 436 Urraulised foreign exchange gain - (83) Ennapces in working capital 483.508 314.038 Changes in working capital: - - Inventories 6.814 36.843 Cash generated from operations 489.826 357.771 Interest paid (54,127) (20,351) Interest paid (54,127) (20,351) Inter	* 0	451 237	277 496
Amortisation of barer plants 20,076 19,086 Depletion of biological assets 2,295 2,459 Amortisation of other intangible assets 596 2,688 Depreciation of right-of-us assets 36,578 35,698 Depreciation of right-of-us assets 3,595 3,330 Deferred income recognised as income (1,862) (1,900) Finance costs 8,643 10,370 Gain on disposal of property, plant and equipment (204) (1,135) Gain on disposal of property, plant and equipment (1,250) - Unrealised foreign exchange gain - (83) Employee benefits 3,457 3,508 Share of profit of equity-accounted investure, net of tax (15,208) (31,23) Operating profit before changes in working capital 483,508 314,038 Changes in working capital: - (23,91) 6,714 Trade and other receivables, prepayments and other assets 8,896 176 Cash generated from operations 489,826 357,771 Increast gaid (44,127) (20,351) <td></td> <td>101,207</td> <td>277,190</td>		101,207	277,190
Depteion of biological assets 2.295 2.498 Amortisation of other intangible assets 36,578 35,698 Depreciation of right-of-use assets 3,595 3,330 Deferred income recognised as income (1,862) (1,900) Finance costs 8,643 10,370 Finance income (2,792) Gain on disposal of property, plant and equipment (2,04) (1,135) Gain on disposal of property investments (1,250) - - Property, plant and equipment writen off 351 436 Unrealised foreign exchange gain - (83) Employee benefits 3,457 3,508 Share of profit of equity-accounted investee, net of tax (3,5028) (3,14,038) Operating profit of equity-accounted investee 8,806 176 Tande and other receivables, prepayments and other assets 8,806 176 Tande and other proveriables, prepayments and other assets 6,814 36,843 Cash generater form operating activities 489,826 357,771 Interest paid (4,4006) (5,694) Income	5 5	20.076	19.086
Amorisation of other intangible assets 596 2.688 Depreciation of right-of-use assets 3.595 3.330 Deferred income recognised as income (1,862) (1,900) Finance costs 8,643 10.370 Gain on disposal of property, plant and equipment (204) (1.135) Gai on disposal of quoted investments (1.200) - Property, plant and equipment written off 3.51 4.36 Unrealised foreign exchange gain - (83) Employee benefits 3.457 3.508 Share of profit of equipt-accounted investee, net of tax (3.51.23) (3.51.23) Operating profit before changes in working capital - (83) Inventories (9,391) 6.714 Trade and other payables - (4.306) (5.694) Income tax piad (4.4006) (5.694) - Income tax piad (4.3006) (5.694) - Income tax piad (4.4006) (5.694) - Income tax piad (4.3035) 330.250 -			
Depreciation of property, plant and equipment $36,578$ $35,598$ Depreciation of right-of-use assets $3,595$ $3,330$ Deferred income recognised as income $(1,802)$ $(1,900)$ Finance costs $8,643$ $10,370$ Finance income $(2,4976)$ $(2,792)$ Gain on disposal of property, plant and equipment (204) $(1,135)$ Gain on disposal of property, plant and equipment witten off 351 436 Unrealised foreign exchange gain- (83) Employee benefits $3,457$ $3,508$ Share of profit of equity-accounted investee, net of tax $(35,028)$ $(35,123)$ Operating profit before changes in working capital483,508 $314,038$ Changes in working capital:Inventories $(9,391)$ $6,714$ -Trade and other payables $6,814$ $36,843$ $36,843$ Cash generated from operations $489,826$ $357,771$ Interest paid $(54,127)$ $(20,351)$ Employee benefits paid (537) $(1,206)$ Net cash from disposal of quoted investments $9,129$ $-$ Addition to biological assets $(4,251)$ $(1,636)$ Proceeds from disposal of quoted investments $9,129$ $-$ Addition to biological assets $(30,817)$ $(25,425)$ Addition to biological assets $(30,817)$ $(25,425)$ Addition to biological assets $(30,817)$ $(25,425)$ Addition to biological assets $(33,817)$ $(25,425)$ <td></td> <td></td> <td>-</td>			-
Deferred income recognised as income (1,862) (1,900) Finance costs 8,643 10370 Finance income (4,976) (2,792) Gain on disposal of property, plant and equipment (204) (1,135) Gain on disposal of property, plant and equipment witten off 351 436 Unrealised foreign exchange gain - (83) Employce benefits 3,457 3,508 Share of profit of equipt-accounted investee, net of tax (35,028) (35,123) Operating profit before changes in working capital 483,508 314,038 Inventories (9,391) 6,714 Trade and other payables 6,814 36,843 Cash generated from operations 489,826 357,771 Interest paid (54,127) (20,351) Employee benefits paid (537) (1,206) Net cash from operating activities 430,356 330,520 Cash generated from operating activities (26,858) (16,538) Proceeds from disposal of quoted investments 9,129 - Acquisition of poperty, plant and e		36,578	
Finance income 8.643 10,370 Finance income (4,976) (2,792) Gain on disposal of property, plant and equipment (204) (1,135) Gain on disposal of quoted investments (1,250) - Property, plant and equipment writen off 351 436 Unrealised foreign exchange gain - (83) Employee benefits 3,457 3,508 Share of profit of equity-accounted investee, net of tax (35,028) (35,123) Operating profit before changes in working capital 483,508 314,038 Changes in working capital: - (8,896) 176 Trade and other receivables, prepayments and other assets 8,896 176 Trade and other receivables, prepayments and other assets 4,89,60 (5,694) Interest paid (5,171) (20,351) (20,351) Interest paid (537) (1,206) 12,2647 Proceeds from disposal of property, plant and equipment (26,858) (16,538) Proceeds from disposal of property, plant and equipment (21,202) 1,2647 Proceeds from		3,595	3,330
Finance income (4.976) (2.792) Gain on disposal of property, plant and equipment (204) (1.135) Gain on disposal of quoted investments (1.250) -Property, plant and equipment writen off 351 436 Unrealised foreign exchange gain- (83) Employee benefits 3.457 3.508 Share of profit of equity-accounted investee, net of tax (35.028) (35.123) Operating profit before changes in working capital:Inventories (9.391) 6.714 Trade and other receivables, prepayments and other assets 8.896 176 7771 Trade and other preceivables, prepayments and other assets 8.896 357.771 $10.523.232$ Income tax piad (44.806) (5.694) (5.694) Income tax piad (45.37) (1.200) (1.200) Net cash from operating activities 9.129 $-$ Addition to property, plant and equipment (26.858) (16.538) Proceeds from disposal of quoted investments 9.129 $-$ Addition to balogical assets (4.251) (1.636) Addition to balogical assets (2.72) $-$ Dividend received from associate (30.817) (25.427) Proceeds from disposal of quoted investments $ (100)$ Net cash used in investing activities $ (100)$ Received from associate (2.72) $-$ Dividend received from associate (2.72) $-$ Dividend treceived from associate $-$ <td< td=""><td>Deferred income recognised as income</td><td>(1,862)</td><td>(1,900)</td></td<>	Deferred income recognised as income	(1,862)	(1,900)
Gain on disposal of property, plant and equipment (204) (1.135) Gain on disposal of quoted investments (1.250) -Property, plant and equipment written off 351 436 Unrealised foreign exchange gain- (83) Employee benefits 3.457 3.508 Share of profit of equity-accounted investee, net of tax $(35,028)$ $(35,123)$ Operating profit before changes in working capital $483,508$ $314,038$ Changes in working capital:- $(6,8)$ Inventories $(9,391)$ $6,714$ Trade and other receivables, prepayments and other assets 8.896 176 Trade and other receivables, prepayments and other assets 8.896 $356,731$ Cash generated from operations $489,826$ 3577.71 Increme tap aid (4406) $(5,694)$ Income tap aid $(54,127)$ $(20,351)$ Employee benefits paid (537) $(1,206)$ Net cash from operating activities $430,356$ $330,520$ Cash form disposal of quoted investments $9,129$ $-$ Acquisition of property, plant and equipment $(26,858)$ $(16,538)$ Proceeds from disposal of quoted investments $9,129$ $-$ Addition to biological assets $(4,251)$ $(1,636)$ Addition to biological assets $(28,7)$ $-$ Cubic difference (28) $(27,6)$ Proceeds from disposal of quoted investments $9,129$ $-$ Cubic difference $(30,744)$ $(29,764)$ Cash			
Gain on disposal of quoted investments $(1,250)$ -Property, plant and equipment written off 351 436 Unrealised foreign exchange gain- (33) Employee benefits $3,457$ $3,508$ Share of profit of equity-accounted investee, net of tax $(35,028)$ $(35,123)$ Operating profit before changes in working capital $483,508$ $314,038$ Changes in working capital:- $(3,91)$ $6,714$ Inventories $(9,391)$ $6,714$ $7ade$ and other payables $6,814$ $36,843$ Cash generated from operations $489,826$ $357,771$ $330,520$ Interest paid $(54,127)$ $(20,351)$ 10000 $(5,694)$ Income tax paid $(54,127)$ $(20,351)$ 100000 $330,520$ Cash from operating activities (337) $(1,206)$ $-$ Acquisition of property, plant and equipment $22,647$ $-$ Proceeds from disposal of property, plant and equipment $22,12$ $2,647$ Proceeds from disposal of quoted investments $9,129$ $-$ Addition to biological assets $(4,251)$ $(1,636)$ Addition to biological assets $(3,637)$ $-$ Orividend received from associate $(2,792)$ $-$ Dividend received from associate $(2,792)$ $-$ Interest profition of shares in subsidiaries $ (100)$ Net cash used in investing activities $(3,78)$ $(2,2764)$ Cash flows from financing activities (373) $(2,207)$ D			
Property, plant and equipment written off 351 436 Unrealised foreign exchange gain - (83) Employee benefits 3,457 3,508 Share of profit of equity-accounted investee, net of tax (35,028) (35,123) Operating profit before changes in working capital 483,508 314,038 Changes in working capital: - - - Inventories (9,391) 6,714 - - Trade and other receivables, prepayments and other assets 8,896 176 - - Cash generated from operations 4489,826 357,771 - (24,806) (5,604) Incentors paid (4,806) (5,604) - (20,351) Employee benefits paid (33,77) (1,206) - - Net cash from operating activities 430,356 - - - Acquisition of property, plant and equipment (26,858) (16,538) - - - - - - - - - - - - - <td></td> <td>· · · ·</td> <td>(1,135)</td>		· · · ·	(1,135)
Urrealised foreign exchange gain.(83)Employee benefits3,4573,508Share of profit of equity-accounted investee, net of tax $(35,028)$ (35,123)Operating profit before changes in working capital483,508314,038Changes in working capital:1483,508314,038Inventories(9,391)6,714Trade and other receivables, prepayments and other assets8,896176Trade and other payables6,81436,843Cash generated from operations489,826357,771Interest paid(4,806)(5,694)Income tax paid(54,127)(20,351)Income tax paid(537)(1,206)Net cash from operating activities430,356330,520Cash flows from investing activities(4,251)(1,653)Proceeds from disposal of property, plant and equipment(26,858)(16,538)Proceeds from disposal of quoted investments9,129-Addition to biological assets(4,251)(1,635)Addition to bearer plants(3,817)(25,425)Addition to barse in associate(2,87)-Unividend received from associate16,7808,496Dividends to owners of the Company(154,162)(110,115)Dividends to owners of the Company(154,162)(2,876)<		(1,250)	-
Employee benefits $3,457$ $3,508$ Share of profit of equity-accounted investee, net of tax $(35,028)$ $(35,123)$ Operating profit before changes in working capital $483,508$ $314,038$ Changes in working capital:Inventories $(9,391)$ $6,714$ Trade and other receivables, prepayments and other assets $8,896$ 176 Trade and other payables $6,814$ $36,843$ Cash generated from operations $489,826$ $357,771$ Interest paid $(4,806)$ $(5,694)$ Income tax paid $(54,127)$ $(20,351)$ Employee benefits paid (537) $(1,206)$ Net cash from operating activities $430,356$ $330,520$ Cash flows from investing activities $430,356$ $330,520$ Cash flows from disposal of property, plant and equipment 221 $2,647$ Proceeds from disposal of property, plant and equipment $(26,858)$ $(16,538)$ Proceeds from disposal of quoted investments $9,129$ $-$ Addition to biological assets $(4,251)$ $(1,636)$ Acquisition of shares in associate (287) $-$ Dividend received from associate $16,780$ $8,496$ Interest received $ (29,764)$ Cash flows from financing activities $ (100)$ Dividends to owners of the Company $(154,162)$ $(110,115)$ Dividends to owners of the Company $(154,162)$ $(110,115)$ Dividends to owners of the Company $ (2,870)$ Hire purchase financing act		351	
Share of profit of equity-accounted investee, net of tax $(35,028)$ $(35,123)$ Operating profit before changes in working capital $483,508$ $314,038$ Changes in working capital: Inventories $(9,391)$ $6,714$ Trade and other receivables, prepayments and other assets $8,896$ 176 Trade and other payables $6,814$ $36,843$ Cash generated from operations $489,826$ $357,771$ Interest paid $(4,806)$ $(5,694)$ Income tax paid $(54,127)$ $(20,351)$ Employee benefits paid $(53,72)$ $(1,206)$ Net cash from operating activities $430,356$ $330,520$ Cash flows from investing activities $9,129$ $-$ Acquisition of property, plant and equipment $(26,858)$ $(16,538)$ Proceeds from disposal of property, plant and equipment $(28,77)$ $-$ Proceeds from disposal of quoted investments $9,129$ $-$ Addition to biological assets $(4,251)$ $(1,636)$ Addition to biological assets $(4,251)$ $(1,636)$ Addition to barer plants $(30,817)$ $(25,425)$ Acquisition of shares in subsidiaries $ (1000)$ Net cash used in investing activities $(30,744)$ $(29,764)$ Cash flows from financing activities $(37,71)$ $(25,425)$ Acquisition of shares in subsidiaries $ (100)$ Net cash used in investing activities $(28,77)$ $-$ Dividends to owners of the Company $(154,162)$ $(110,115)$ Div		-	. ,
Operating profit before changes in working capital $483,508$ $314,038$ Changes in working capital: Inventories(9,391) $6,714$ Trade and other receivables, prepayments and other assets $8,896$ 176 Trade and other payables $6,814$ $36,843$ Cash generated from operations $489,826$ $357,771$ Interest paid(4,806) $(5,694)$ Income tax paid $(54,127)$ $(20,351)$ Employee benefits paid (537) $(1,206)$ Net cash from operating activities $430,356$ $330,250$ Cash flows from investing activities $9,129$ $-$ Acquisition of property, plant and equipment 221 $2,647$ Proceeds from disposal of property, plant and equipment 221 $2,647$ Proceeds from disposal of guoted investments $9,129$ $-$ Addition to biological assets $(4,251)$ $(1,6538)$ Addition to biological assets $(26,780)$ $8,496$ Interest received $4,976$ $2,792$ Proceeds from disposal of no controlling interests 363 $-$ Subscription of shares in subsidiaries $ (100)$ Net cash used in investing activities $(37,74)$ $(29,764)$ Cash flows from financing activities $ (28,70)$ Payment of borowings/trade financing $(81,401)$ $(87,889)$ Payment of borowings/trade financing (378) (250) Dividends to owners of the Company $(154,162)$ $(110,115)$ Dividends to owners of the Company $(1$,
Changes in working capital: InventoriesInventories $(9,391)$ 6.714 Trade and other receivables, prepayments and other assets 8.896 176 Trade and other receivables, prepayments and other assets 6.814 36.843 Cash generated from operations 489.826 357.771 Interest paid (4.806) (5.694) Income tax paid (537) (1.206) Net cash from operating activities 430.356 330.520 Cash flows from investing activitiesAcquisition of property, plant and equipment (26.858) (16.538) Proceeds from disposal of property, plant and equipment 221 2.647 Proceeds from disposal of property, plant and equipment (2275) $-$ Addition to biological assets (4.251) (1.636) Addition to bearer plants (30.817) (25.425) Acquisition of shares in associate (287) $-$ Dividend received from associate $16,780$ 8.496 Interest received 4.976 2.792 Proceeds from shares issued to non controlling interests 363 $-$ Subscription of shares in subsidiaries $ (1000)$ Net cash used in investing activities (15.176) (110.115) Dividends to owners of the Company (154.162) (110.115) Dividends to owners of the Company (154.162) (110.115) Dividends to owners of the Company (154.66) (228.78) Payment of lease liabilities $ (2.870$			
Inventories $(9,391)$ $6,714$ Trade and other payables $6,814$ $36,843$ Cash generated from operations $489,826$ $357,771$ Interest paid $(4,806)$ $(5,644)$ Income tax paid $(54,127)$ $(20,351)$ Employee benefits paid $(54,127)$ $(20,351)$ Employee benefits paid $(54,127)$ $(20,351)$ Employee benefits paid $(54,127)$ $(20,351)$ Proceeds from investing activities $430,356$ $330,520$ Cash flows from investing activities $9,129$ $-$ Acquisition of property, plant and equipment 221 $2,647$ Proceeds from disposal of property, plant and equipment $9,129$ $-$ Addition to biological assets $(4,251)$ $(1,636)$ Addition to biological assets $(4,251)$ $(1,636)$ Addition to barer plants $(30,817)$ $(25,425)$ Acquisition of shares in associate (287) $-$ Dividend received from associate $4,976$ $2,792$ Proceeds from shares insubsidiaries $ (100)$ Net cash used in investing activities 363 $-$ Dividends to owners of the Company $(154,162)$ $(110,115)$ Dividends to owners of the Company $(154,162)$ $(110,115)$ Dividends to one-controlling interests (378) (250) Repayment of borrowings/trade financing (314) $(3,289)$ Payment of lease liabilities $ (2,870)$ Payment of lease liabilities $ (2,870)$	Operating profit before changes in working capital	483,508	314,038
Inventories $(9,391)$ $6,714$ Trade and other receivables, prepayments and other assets $8,896$ 176 Trade and other receivables, prepayments and other assets $8,896$ 176 Trade and other receivables, prepayments and other assets $8,896$ 176 Trade and other payables $6,814$ $36,843$ Cash generated from operations $489,826$ $357,771$ Interest paid $(4,806)$ $(5,694)$ Income tax paid (537) $(1,206)$ Employce benefits paid (537) $(1,206)$ Net cash from operating activities $430,356$ $330,520$ Cash flows from investing activities $430,356$ $330,520$ Cash flows from investing activities $9,129$ $-$ Proceeds from disposal of property, plant and equipment 221 $2,647$ Proceeds from disposal of quoted investments $9,129$ $-$ Addition to biological assets $(4,251)$ (1.636) Addition to bearer plants $(30,817)$ $(25,425)$ Acquisition of shares in associate $16,780$ $8,496$ Interest received $4,976$ $2,792$ Proceeds from shares issued to non controlling interests 363 $-$ Subscription of shares in subsidiaries $ (1000)$ Net cash used in investing activities $ (2,870)$ Dividends to owners of the Company $(154,162)$ $(110,115)$ Dividends to owners of the Company $(154,162)$ $(110,115)$ Dividends to owners of the Company $(154,162)$ <t< td=""><td>~</td><td></td><td></td></t<>	~		
Trade and other receivables, prepayments and other assets $8,896$ 176 Trade and other payables $6,814$ $36,843$ Cash generated from operations $489,826$ $357,771$ Interest paid $(4,806)$ $(5,694)$ Income tax paid $(54,127)$ $(20,351)$ Employee benefits paid $(54,127)$ $(20,351)$ Net cash from operating activities $430,356$ $330,520$ Cash flows from investing activitiesAcquisition of property, plant and equipment 221 $2,647$ Proceeds from disposal of property, plant and equipment 221 $2,647$ Proceeds from disposal of quoted investments $9,129$ -Addition to biological assets $(4,251)$ $(1,636)$ Addition to bological assets (287) -Dividend received from associate $16,780$ $8,496$ Interest received $4,976$ $2,792$ Proceeds from financing activities $ (100)$ Net cash used in investing activities $(30,744)$ $(29,764)$ Dividends to owners of the Company $(15,176)$ $(2,600)$ Repayment of borrowing/trade financing $(31,401)$ $(87,889)$ Payment of lease financing interests (378) (250) Term loan interest/profit paid $(3,489)$ $(4,644)$ Net cash used in financing activities $(254,606)$ $(208,368)$ Net cash used in financing activities $(274,06)$ $(274,06)$ Term loan interest/profit paid (378) (250) Term loan int		(0.201)	6714
Trade and other payables $6,814$ $36,843$ Cash generated from operations $4489,826$ $357,771$ Interest paid $(4,806)$ $(5,694)$ Income tax paid $(54,127)$ $(20,351)$ Employee benefits paid (537) $(1,206)$ Net cash from operating activities $430,356$ $330,520$ Cash flows from investing activities $430,356$ $330,520$ Cash flows from investing activities 221 $2,647$ Proceeds from disposal of property, plant and equipment 221 $2,647$ Proceeds from disposal of quoted investments $9,129$ -Addition to biological assets $(4,251)$ $(1,636)$ Addition to bearer plants $(30,817)$ $(25,425)$ Acquisition of shares in associate (287) -Dividend received from associate $16,780$ $8,496$ Interest received $4,976$ $2,792$ Proceeds from financing activities $(30,744)$ $(29,764)$ Cash flows from financing activities $(15,176)$ $(2,600)$ Net cash used in investing activities $(15,176)$ $(2,600)$ Dividends to owners of the Company $(154,162)$ $(110,115)$ Dividends to owners of the Company $(154,162)$ $(110,115)$ Dividends to owners of the Company $(154,76)$ $(2,600)$ Repayment of lease liabilities $ (2,870)$ Hire purchase financing interests paid (378) (250) Term loan interest/profit paid $(24,646)$ $(23,489)$ Net cash used			
Cash generated from operations $489,826$ $357,771$ Interest paid $(4,806)$ $(5,694)$ Income tax paid $(54,127)$ $(20,351)$ Employee benefits paid (537) $(1,206)$ Net cash from operating activities $430,356$ $330,520$ Cash flows from investing activitiesAcquisition of property, plant and equipment $(26,858)$ $(16,538)$ Proceeds from disposal of property, plant and equipment 221 $2,647$ Proceeds from disposal of quoted investments $9,129$ $-$ Addition to biological assets $(4,251)$ (1.636) Addition to biological assets (287) $-$ Dividend received from associate $16,780$ $8,496$ Interest received $4,976$ $2,792$ Proceeds from shares in subsidiaries $ (100)$ Net cash used in investing activities $(30,744)$ $(29,764)$ Dividends to on-controlling interests 363 Subscription of shares of the Company $(154,162)$ $(110,115)$ Dividends to on-controlling interests $(33,78)$ (250) Repayment of borrowings/trade financing $(3,78)$ (250) Payment of lease liabilities $ (2,870)$			
Interest paid $(4,806)$ $(5,694)$ Income tax paid $(54,127)$ $(20,351)$ Employee benefits paid $(54,127)$ $(20,351)$ Net cash from operating activities $430,356$ $330,520$ Cash flows from investing activities 221 $2,647$ Proceeds from disposal of property, plant and equipment 221 $2,647$ Proceeds from disposal of quoted investments $9,129$ $-$ Addition to biological assets $(4,251)$ $(1,636)$ Addition to baares in associate (287) $-$ Dividend received from associate $16,780$ $8,496$ Interest received $4,976$ $2,792$ Proceeds from shares issued to non controlling interests 363 $-$ Subscription of shares in subsidiaries $ (100)$ Net cash used in investing activities $(33,744)$ $(29,764)$ Cash flows from financing activities (378) (250) Dividends to owners of the Company $(154,162)$ $(110,115)$ Dividends to owners of the Company $(154,162)$ $(28,700)$ Hire purchase financing interests (378) (250) Term loan interest/profit paid $(3,489)$ $(4,644)$ Net cash used in financing activities $(254,606)$ $(2208,368)$ Net increase in cash and cash equivalents $145,006$			
Income tax paid $(54,127)$ $(20,351)$ Employee benefits paid (537) $(1,206)$ Net cash from operating activities $430,356$ $330,520$ Cash flows from investing activitiesAcquisition of property, plant and equipment $(26,858)$ $(16,538)$ Proceeds from disposal of property, plant and equipment 221 $2,647$ Proceeds from disposal of quoted investments $9,129$ -Addition to biological assets $(4,251)$ $(1,636)$ Addition to bearer plants $(30,817)$ $(25,425)$ Acquisition of shares in associate (287) -Dividend received from associate $16,780$ $8,496$ Interest received $4,976$ $2,792$ Proceeds from financing activities $(30,744)$ $(29,764)$ Cash flows from financing activitiesDividends to non-controlling interests 363 -Subscription of shares of the Company $(154,162)$ $(110,115)$ Dividends to owners of the Company $(154,162)$ $(110,115)$ Dividends to non-controlling interests (378) (250) Hire purchase financing interest paid (378) (250) Hire purchase financing activities $(234,606)$ $(208,368)$ Net cash used in financing activities $(254,606)$ $(208,368)$ Net increase in cash and cash equivalents $145,006$ $92,387$ Effect of exchange rate fluctuations on cash held (12) (274) Cash and cash equivalents to acash held (12) (274)	e i		
Employee benefits paid (537) $(1,206)$ Net cash from operating activities $430,356$ $330,520$ Cash flows from investing activitiesAcquisition of property, plant and equipment $(26,858)$ $(16,538)$ Proceeds from disposal of property, plant and equipment 221 $2,647$ Proceeds from disposal of quoted investments $9,129$ -Addition to biological assets $(4,251)$ $(1,636)$ Addition to biological assets $(30,817)$ $(25,425)$ Acquisition of shares in associate (287) -Dividend received from associate $16,780$ $8,496$ Interest received $4,976$ $2,792$ Proceeds from shares in subsidiaries- (100) Net cash used in investing activities 363 -Dividends to one-controlling interests 363 -Subscription of shares of the Company $(154,162)$ $(110,115)$ Dividends to one-controlling interests $(30,7144)$ $(29,764)$ Cash flows from financing activitiesDividends to non-controlling interests $(3,78)$ (250) Term loan interest/profit paid $(3,78)$ (250) Net cash used in investing activities $(254,606)$ $(208,368)$ Net increase in cash and cash equivalents $145,006$ $92,387$ Effect of exchange rate fluctuations on cash held (12) (274) Cash and cash equivalents at 1 January $454,945$ $271,358$			
Net cash from operating activities430,356330,520Cash flows from investing activitiesAcquisition of property, plant and equipment2212,647Proceeds from disposal of quoted investments9,129-Addition to biological assets(4,251)(1,636)Addition to bearer plants(30,817)(25,425)Acquisition of shares in associate(287)-Dividend received from associate16,7808,496Interest received4,9762,792Proceeds from shares insubidiaries-(100)Net cash used in investing activities363-Cash flows from financing activities(30,744)(29,764)Cash flows from financing activities(154,162)(110,115)Dividends to owners of the Company(154,162)(110,115)Dividends to non-controlling interests(15,176)(2,600)Repayment of borrowings/trade financing(81,401)(87,889)Payment of lease liabilities-(2,870)Hire purchase financing interest paid(378)(250)Term loan interest/profit paid(3,489)(4,644)Net cash used in financing activities(254,606)(208,368)Net increase in cash and cash equivalents145,00692,387Effect of exchange rate fluctuations on cash held(12)(274)Cash and cash equivalents on cash held(12)(274)Cash and cash equivalents145,945271,358			
Cash flows from investing activitiesAcquisition of property, plant and equipment(26,858)Proceeds from disposal of property, plant and equipment221Proceeds from disposal of quoted investments9,129Addition to biological assets(4,251)Addition to bearer plants(30,817)Acquisition of shares in associate(287)Dividend received from associate16,7808,49611terest received10004,9762,792-Proceeds from financing activities-0(30,744)0(29,764)Cash flows from financing activities0(15,176)0(2,600)Repayment of borrowings/trade financing(81,401)0(378)0(254,006)1(28,700)Hire purchase financing interest paid(378)0(254,006)1(20,368)Net cash used in financing activities(254,606)1(20,368)1(12)1(24,606)1(20,368)1(20,368)1(12)1(24,606)1(20,368)1(12)2(274,00)2(224,606)2(203,368)2(12)2(274,00)3(200,368)2(12)3(21)3(224,606)3(2			
Acquisition of property, plant and equipment(26,858)(16,538)Proceeds from disposal of property, plant and equipment2212,647Proceeds from disposal of quoted investments9,129-Addition to biological assets(4,251)(1,636)Addition to bearer plants(30,817)(25,425)Acquisition of shares in associate(287)-Dividend received from associate16,7808,496Interest received4,9762,792Proceeds from shares issued to non controlling interests363-Subscription of shares in subsidiaries-(100)Net cash used in investing activities(30,744)(29,764)Cash flows from financing activitiesDividends to owners of the Company(154,162)(110,115)Dividends to non-controlling interests(15,776)(2,600)Repayment of borrowings/trade financing(81,401)(87,889)Payment of lease liabilities-(2,870)Hire purchase financing activities(378)(250)Term loan interest/profit paid(3,489)(4,644)Net cash used in financing activities(254,606)(208,368)Net increase in cash and cash equivalents145,00692,387Effect of exchange rate fluctuations on cash held(12)(274)Cash and cash equivalents at 1 January454,945271,358	Net cash from operating activities	430,336	330,520
Acquisition of property, plant and equipment(26,858)(16,538)Proceeds from disposal of property, plant and equipment2212,647Proceeds from disposal of quoted investments9,129-Addition to biological assets(4,251)(1,636)Addition to bearer plants(30,817)(25,425)Acquisition of shares in associate(287)-Dividend received from associate16,7808,496Interest received4,9762,792Proceeds from shares issued to non controlling interests363-Subscription of shares in subsidiaries-(100)Net cash used in investing activities(30,744)(29,764)Cash flows from financing activitiesDividends to owners of the Company(154,162)(110,115)Dividends to non-controlling interests(15,776)(2,600)Repayment of borrowings/trade financing(81,401)(87,889)Payment of lease liabilities-(2,870)Hire purchase financing activities(378)(250)Term loan interest/profit paid(3,489)(4,644)Net cash used in financing activities(254,606)(208,368)Net increase in cash and cash equivalents145,00692,387Effect of exchange rate fluctuations on cash held(12)(274)Cash and cash equivalents at 1 January454,945271,358	Cash flows from investing activities		
Proceeds from disposal of property, plant and equipment2212,647Proceeds from disposal of quoted investments9,129-Addition to biological assets(4,251)(1,636)Addition to bearer plants(30,817)(25,425)Acquisition of shares in associate(287)-Dividend received from associate16,7808,496Interest received4,9762,792Proceeds from shares issued to non controlling interests363-Subscription of shares in subsidiaries-(100)Net cash used in investing activities(30,744)(29,764)Cash flows from financing activities(154,162)(110,115)Dividends to owners of the Company(154,162)(110,115)Dividends to non-controlling interests(15,176)(2,600)Repayment of bares financing(81,401)(87,889)Payment of lease liabilities-(2,870)Hire purchase financing interest paid(378)(250)Term loan interest/profit paid(3,489)(4,644)Net cash used in financing activities(254,606)(208,368)Net increase in cash and cash equivalents145,00692,387Effect of exchange rate fluctuations on cash held(12)(274)Cash and cash equivalents at 1 January454,945271,358		(26,858)	(16,538)
Proceeds from disposal of quoted investments9,129-Addition to biological assets(4,251)(1,636)Addition to bearer plants(30,817)(25,425)Acquisition of shares in associate(287)-Dividend received from associate16,7808,496Interest received4,9762,792Proceeds from shares in subsidiaries-(100)Net cash used in investing activities363-Dividends to owners of the Company(154,162)(110,115)Dividends to owners of the Company(154,162)(110,115)Dividends to non-controlling interests(30,744)(29,764)Cash flows from financing activitiesDividends to owners of the Company(154,162)(110,115)Dividends to non-controlling interests(15,176)(2,600)Repayment of borrowings/trade financing(81,401)(87,889)Payment of lease liabilities-(2,870)Hire purchase financing interest paid(378)(250)Term loan interest/profit paid(3,489)(4,644)Net cash used in financing activities(254,606)(208,368)Net increase in cash and cash equivalents145,00692,387Effect of exchange rate fluctuations on cash held(12)(274)Cash and cash equivalents at 1 January454,945271,358		221	2,647
Addition to biological assets $(4,251)$ $(1,636)$ Addition to bearer plants $(30,817)$ $(25,425)$ Acquisition of shares in associate (287) -Dividend received from associate $16,780$ $8,496$ Interest received $4,976$ $2,792$ Proceeds from shares issued to non controlling interests 363 -Subscription of shares in subsidiaries $ (100)$ Net cash used in investing activities $(30,744)$ $(29,764)$ Cash flows from financing activitiesDividends to owners of the Company $(154,162)$ $(110,115)$ Dividends to onon-controlling interests $(15,176)$ $(2,600)$ Repayment of borrowings/trade financing $(81,401)$ $(87,889)$ Payment of lease liabilities $ (250)$ Term loan interest/profit paid $(3,489)$ $(4,644)$ Net cash used in financing activities $(254,606)$ $(208,368)$ Net increase in cash and cash equivalents $145,006$ $92,387$ Effect of exchange rate fluctuations on cash held (12) (274) Cash and cash equivalents at 1 January $454,945$ $271,358$		9,129	-
Acquisition of shares in associate(287)-Dividend received from associate16,7808,496Interest received4,9762,792Proceeds from shares issued to non controlling interests363-Subscription of shares in subsidiaries-(100)Net cash used in investing activities(30,744)(29,764)Cash flows from financing activitiesDividends to owners of the Company(154,162)(110,115)Dividends to owners of the Company(15,176)(2,600)Repayment of borrowings/trade financing(81,401)(87,889)Payment of lease liabilities-(2,870)Hire purchase financing interest paid(378)(250)Term loan interest/profit paid(3,489)(4,644)Net cash used in financing activities145,00692,387Effect of exchange rate fluctuations on cash held(12)(274)Cash and cash equivalents at 1 January454,945271,358		(4,251)	(1,636)
Dividend received from associate16,7808,496Interest received4,9762,792Proceeds from shares issued to non controlling interests363-Subscription of shares in subsidiaries-(100)Net cash used in investing activities(30,744)(29,764)Cash flows from financing activitiesDividends to owners of the Company(154,162)(110,115)Dividends to onn-controlling interests(15,176)(2,600)Repayment of borrowings/trade financing(81,401)(87,889)Payment of lease liabilities-(2,870)Hire purchase financing interest paid(378)(250)Term loan interest/profit paid(3,489)(4,644)Net cash used in financing activities145,00692,387Effect of exchange rate fluctuations on cash held(12)(274)Cash and cash equivalents at 1 January454,945271,358	Addition to bearer plants	(30,817)	(25,425)
Interest received4,9762,792Proceeds from shares issued to non controlling interests363-Subscription of shares in subsidiaries-(100)Net cash used in investing activities(30,744)(29,764)Cash flows from financing activitiesDividends to owners of the Company(154,162)(110,115)Dividends to non-controlling interests(15,176)(2,600)Repayment of borrowings/trade financing(81,401)(87,889)Payment of lease liabilities-(2,870)Hire purchase financing interest paid(378)(250)Term loan interest/profit paid(3,489)(4,644)Net cash used in financing activities145,00692,387Effect of exchange rate fluctuations on cash held(12)(274)Cash and cash equivalents at 1 January454,945271,358	Acquisition of shares in associate	(287)	-
Proceeds from shares issued to non controlling interests363Subscription of shares in subsidiaries-(100)Net cash used in investing activities(30,744)(29,764)Cash flows from financing activities(154,162)(110,115)Dividends to owners of the Company(154,162)(110,115)Dividends to non-controlling interests(15,176)(2,600)Repayment of borrowings/trade financing(81,401)(87,889)Payment of lease liabilities-(2,870)Hire purchase financing interest paid(378)(250)Term loan interest/profit paid(3,489)(4,644)Net cash used in financing activities(254,606)(208,368)Net increase in cash and cash equivalents145,00692,387Effect of exchange rate fluctuations on cash held(12)(274)Cash and cash equivalents at 1 January454,945271,358	Dividend received from associate	16,780	8,496
Subscription of shares in subsidiaries-(100)Net cash used in investing activities(30,744)(29,764)Cash flows from financing activities(154,162)(110,115)Dividends to owners of the Company(154,162)(110,115)Dividends to non-controlling interests(15,176)(2,600)Repayment of borrowings/trade financing(81,401)(87,889)Payment of lease liabilities-(2,870)Hire purchase financing interest paid(378)(250)Term loan interest/profit paid(3,489)(4,644)Net cash used in financing activities145,00692,387Effect of exchange rate fluctuations on cash held(12)(274)Cash and cash equivalents at 1 January454,945271,358	Interest received	4,976	2,792
Net cash used in investing activities(30,744)(29,764)Cash flows from financing activities(154,162)(110,115)Dividends to owners of the Company(154,162)(110,115)Dividends to non-controlling interests(15,176)(2,600)Repayment of borrowings/trade financing(81,401)(87,889)Payment of lease liabilities-(2,870)Hire purchase financing interest paid(378)(250)Term loan interest/profit paid(3,489)(4,644)Net cash used in financing activities145,00692,387Effect of exchange rate fluctuations on cash held(12)(274)Cash and cash equivalents at 1 January454,945271,358	Proceeds from shares issued to non controlling interests	363	-
Cash flows from financing activitiesDividends to owners of the Company(154,162)(110,115)Dividends to non-controlling interests(15,176)(2,600)Repayment of borrowings/trade financing(81,401)(87,889)Payment of lease liabilities-(2,870)Hire purchase financing interest paid(378)(250)Term loan interest/profit paid(3,489)(4,644)Net cash used in financing activities145,00692,387Effect of exchange rate fluctuations on cash held(12)(274)Cash and cash equivalents at 1 January454,945271,358	Subscription of shares in subsidiaries		(100)
Dividends to owners of the Company(154,162)(110,115)Dividends to non-controlling interests(15,176)(2,600)Repayment of borrowings/trade financing(81,401)(87,889)Payment of lease liabilities-(2,870)Hire purchase financing interest paid(378)(250)Term loan interest/profit paid(3,489)(4,644)Net cash used in financing activities(254,606)(208,368)Net increase in cash and cash equivalentsEffect of exchange rate fluctuations on cash held(12)(274)Cash and cash equivalents at 1 January454,945271,358	Net cash used in investing activities	(30,744)	(29,764)
Dividends to owners of the Company(154,162)(110,115)Dividends to non-controlling interests(15,176)(2,600)Repayment of borrowings/trade financing(81,401)(87,889)Payment of lease liabilities-(2,870)Hire purchase financing interest paid(378)(250)Term loan interest/profit paid(3,489)(4,644)Net cash used in financing activities(254,606)(208,368)Net increase in cash and cash equivalentsEffect of exchange rate fluctuations on cash held(12)(274)Cash and cash equivalents at 1 January454,945271,358			
Dividends to non-controlling interests(15,176)(2,600)Repayment of borrowings/trade financing(81,401)(87,889)Payment of lease liabilities-(2,870)Hire purchase financing interest paid(378)(250)Term loan interest/profit paid(3,489)(4,644)Net cash used in financing activities(254,606)(208,368)Net increase in cash and cash equivalents145,00692,387Effect of exchange rate fluctuations on cash held(12)(274)Cash and cash equivalents at 1 January454,945271,358		(154 162)	(110,115)
Repayment of borrowings/trade financing(81,401)(87,889)Payment of lease liabilities-(2,870)Hire purchase financing interest paid(378)(250)Term loan interest/profit paid(3,489)(4,644)Net cash used in financing activities(254,606)(208,368)Net increase in cash and cash equivalentsEffect of exchange rate fluctuations on cash held(12)(274)Cash and cash equivalents at 1 January454,945271,358			
Payment of lease liabilities-(2,870)Hire purchase financing interest paid(378)(250)Term loan interest/profit paid(3,489)(4,644)Net cash used in financing activities(254,606)(208,368)Net increase in cash and cash equivalentsEffect of exchange rate fluctuations on cash held(12)(274)Cash and cash equivalents at 1 January454,945271,358			
Hire purchase financing interest paid(378)(250)Term loan interest/profit paid(3,489)(4,644)Net cash used in financing activities(254,606)(208,368)Net increase in cash and cash equivalents145,00692,387Effect of exchange rate fluctuations on cash held(12)(274)Cash and cash equivalents at 1 January454,945271,358		(81,401)	
Term loan interest/profit paid(3,489)(4,644)Net cash used in financing activities(254,606)(208,368)Net increase in cash and cash equivalents145,00692,387Effect of exchange rate fluctuations on cash held(12)(274)Cash and cash equivalents at 1 January454,945271,358		(378)	
Net cash used in financing activities(254,606)(208,368)Net increase in cash and cash equivalents145,00692,387Effect of exchange rate fluctuations on cash held(12)(274)Cash and cash equivalents at 1 January454,945271,358			
Net increase in cash and cash equivalents145,00692,387Effect of exchange rate fluctuations on cash held(12)(274)Cash and cash equivalents at 1 January454,945271,358			
Effect of exchange rate fluctuations on cash held(12)(274)Cash and cash equivalents at 1 January454,945271,358	The cash used in financing activities	(234,000)	(200,508)
Effect of exchange rate fluctuations on cash held(12)(274)Cash and cash equivalents at 1 January454,945271,358	Net increase in cash and cash equivalents	145,006	92,387
Cash and cash equivalents at 1 January454,945271,358	-		
	Cash and cash equivalents at 1 January	454,945	271,358
	Cash and cash equivalents at 30 September (Note 22)	599,939	363,471

The unaudited condensed consolidated statement of cash flows should be read in conjunction with the audited financial statements for the year ended 31 December 2021 and the accompanying explanatory notes attached to the interim financial statements.

Notes to the interim financial report

1 Basis of Preparation

The interim financial report has been prepared in accordance with MFRS 134: *Interim Financial Reporting* and paragraph 9.22 of Listing Requirements of the Bursa Malaysia Securities Berhad.

The preparation of an interim financial report in conformity with MFRS 134: *Interim Financial Reporting*, requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses on a year-to-date basis. Actual results may differ from these estimates.

This interim financial report should be read in conjunction with the audited financial statements for the year ended 31 December 2021. It contains unaudited condensed consolidated financial statements and selected explanatory notes. The notes include an explanation of events and transactions that are significant to an understanding of the changes in financial position and performance of the Group since the year ended 31 December 2021. The condensed consolidated interim financial report and notes thereon do not include all of the information required for a full set of financial statements prepared in accordance with Malaysian Financial Reporting Standards (MFRS).

The statutory financial statements for the year ended 31 December 2021 are available from the Company's registered office.

2 Significant Accounting Policies

The significant accounting policies adopted in the preparation of this interim financial report are consistent with those in the audited financial statements for the year ended 31 December 2021, except for the adoption of the following accounting standards, amendments and interpretations:

- Amendments to MFRS 16, Leases Covid-19-Related Rent Concessions beyond 30 June 2021
- Amendments to MFRS 3, Business Combinations Reference to the Conceptual Framework
- Amendments to MFRS 9, Financial Instruments (Annual Improvements to MFRS Standards 2018-2020)
- Amendments to Illustrative Examples accompanying MFRS 16, Leases (Annual Improvements to MFRS Standards 2018-2020)
- Amendments to MFRS 116, Property, Plant and Equipment Proceeds before Intended Use
- Amendments to MFRS 137, Provisions, Contingents Liabilities and Contingents Assets Onerous Contracts Cost of Fulfilling a Contract
- Amendments to MFRS 141, Agriculture (Annual Improvements to MFRS Standards 2018 2020)

The adoption of the accounting standards, amendments and interpretations has no material impact to the Group's consolidated financial statements of the current quarter or the comparative consolidated financial statements of the prior financial year.

3 Auditors' Report on Preceding Annual Financial Statements

The auditors have expressed an unqualified opinion on the audited financial statements for the year ended 31 December 2021 in their report dated 05 April 2022.

4 Seasonality or Cyclicality of Operations

The Group's operations were not subject to any seasonal or cyclical changes for the current quarter under review.

5 Unusual Items

There are no unusual items that have any material impact on the interim financial report.

Notes to the interim financial report

6 Changes in Estimates

There were no changes in estimates that have had a material effect on the current quarter and financial year-todate results.

7 Debt and Equity Securities, Share Buy-back

There were no issuances or repayment of debt or equity securities during the financial quarter under review.

As at 30 September 2022, the number of ordinary shares repurchased in an earlier period and retained as treasury shares is 4,382,000 shares.

8 Dividend

A third interim single-tier ordinary dividend of 15 sen per ordinary share for the financial year ended 31 December 2022, amounting to RM66,069,285 was declared on 29 August 2022 and paid on 05 Oct 2022 to depositors registered in the Record of Depositors at the close of business on 14 September 2022.

The Board of Directors has declared fourth interim single-tier ordinary dividend for the financial year ending 31 December 2022 of 10 sen per ordinary share (corresponding period in Year 2021: 20 sen) to be paid on 20 January 2023 to depositors whose names appear in the Record of Depositors on 3 January 2023.

A depositor shall qualify for entitlement only in respect of:

- (a) Securities transferred into Depositor's Securities Account before 4:00 p.m. on 3 January 2023 in respect of transfers; and
- (b) Securities bought on Bursa Malaysia Securities Berhad on a cum entitlement basis according to the rules of the Bursa Malaysia Securities Berhad.

9 Segmental Reporting

	Revenue from extern	nal customers	Profit before	e tax		
		9 months ended 30 September				
	2022	2021	2022	2021		
	RM'000	RM'000	RM'000	RM'000		
Timber products	313,776	227,730	75,282	18,103		
Oil palm	1,420,843	1,053,558	374,680	258,483		
Others	2,174	1,534	1,275	910		
	1,736,793	1,282,822	451,237	277,496		

10 Valuation of Property, Plant and Equipment

There were no valuation of property, plant and equipment of the Group during the financial quarter under review.

11 Subsequent Events

There were no significant events that have occurred during the interval between the end of the current quarter and the date of this announcement.

Notes to the interim financial report

12 Changes in Composition of the Group

There were no changes in the composition of the Group during the financial quarter under review.

13 Contingent Liabilities or Assets

There were no material changes in the contingent liabilities or assets since the last annual reporting date.

14 Trade and Other Receivables

	As At 30 September 2022 RM'000	As At 31 December 2021 RM'000
Current assets		
Trade receivables	33,863	41,574
Other receivables	1,299	11,448
Deposits	3,419	4,031
Prepayments		
-Plant and machinery	1,480	2,584
-Others	10,007	7,831
	50,068	67,468

15 Capital Commitments

	As At 30 September 2022 RM'000
Property, plant and equipment	101
- Contracted but not provided for	181

16 Review of Performance

(a) For the quarter under review, the Group reported a revenue of RM594.89 million as compared to RM486.86 million recorded in the corresponding quarter in 2021. The Group's profit before tax and its net profit were RM160.96 million and RM127.72 million respectively for the quarter under review as compared to RM125.99 million and RM125.97 million for the corresponding quarter in 2021.

The Group posted a 28% increase in profit in 3Q'22 mainly attributed to higher average selling prices achieved for the Crude Palm Oil ('CPO') and plywood products by 6% and 36% respectively coupled with higher CPO sales volume achieved by 18%.

The Group had recognised a gain of RM5.20 million from the changes in the fair value of the biological assets during the current quarter under review as compared to a gain of RM26.09 million in the preceding corresponding quarter.

Notes to the interim financial report

(b) For the first nine months of 2022, the Group's revenue and net profit were RM1.74 billion and RM362.95 million respectively as compared to RM1.28 billion and RM264.20 million of the corresponding period in year 2021.

Average selling prices of CPO, FFB and plywood products increased by 33%, 26% and 40% respectively resulting in the increments in revenue and profit.

The Group had recognised a gain from the changes in the fair value of the biological assets amounting to RM13.43 million during the current period under review as compared to a gain of RM46.80 million in the preceding corresponding period.

17 Variation of Results compared to the Preceding Quarter

The Group recorded a revenue and profit before tax of RM594.89 million and RM160.96 million respectively in the quarter under review as compared to RM654.15 million and RM175.46 million respectively in the preceding quarter.

Weaker CPO and FFB average selling prices by 32% and 42% respectively contributed to the lower profit performance despite higher sales volume achieved for CPO and FFB by 39% and 33% respectively.

18 Current Year Prospects

Higher production volume and prices for both logs and plywood products that coupled with the appreciation of US dollar, the timber division is anticipated to achieve better YoY performance.

With Quarter 4 being on a declining FFB crop trend in the region, there could therefore be a discounted price gap between Vege oil and Crude Palm Oil. Coupled with uncertainties in both the climatic conditions in major agricultural commodity producing regions and the interruption of the fertiliser supply chain, the Group is positive on the sustainability of the current CPO price trend.

Despite global economic challenges and inflationary pressure, the Group focuses on stringent cost control and productivities to maintain its profit margins. Therefore, barring any unforeseen circumstances, the Board of Directors is confident that the Group will achieve a satisfactory financial performance for financial year 2022.

19 Profit Forecast

Not applicable as the Group did not publish any profit forecast.

TA ANN HOLDINGS BERHAD

Notes to the interim financial report

20 Profit after change in fair value of biological assets

	Individual Quarter 3 months ended 30 September		Cumulative Quart 9 months ended 30 September	
	2022 RM'000	2021 RM'000	2022 RM'000	2021 RM'000
Profit after change in fair value of biological assets is arrived at after crediting/(charging):		INVI UUU	NIVI UUU	IX1VI 000
Finance income	2,139	1,012	4,976	2,792
Finance costs	(2,853)	(3,244)	(8,643)	(10,370)
Depreciation and amortisation	(19,913)	(22,431)	(63,140)	(63,261)
Gain on disposal of quoted investments	-	-	1,250	-
Gain on disposal of property, plant and equipment	170	124	204	1,135
Property, plant and equipment written off	(124)	(298)	(351)	(436)
Foreign exchange gain / (loss)				
- realised	4,048	2,533	8,295	5,680
- unrealised	-	(10)	-	83

Save as disclosed above, the other items required to be disclosed under Appendix 9B, Part A (16) of the Bursa Listing Requirements are not applicable.

Notes to the interim financial report

21 Tax Expense

The taxation charges of the Group for the period under review are as follows:

	Individual Quarter 3 months ended 30 September		Cumu Qua 9 month 30 Sept	rter
	2022	2021	2022	2021
Income tax expense	RM'000	RM'000	RM'000	RM'000
continuing operations	38,438	26,118	101,721	60,096
Share of tax of equity-accounted				
associates	2,446	4,304	11,061	11,091
Total taxation	40,884	30,422	112,782	71,187
Current tax expense				
- Current year	29,794	20,715	77,129	48,095
- Prior year	(702)	(368)	(702)	(368)
	29,092	20,347	76,427	47,727
Deferred tax expense - Current year	0.246	5 771	25 204	12 260
- Current year	9,346	5,771	25,294	12,369
Share of tax of equity-accounted				
associates	2,446	4,304	11,061	11,091
Total tax expense	40,884	30,422	112,782	71,187
Reconciliation of tax expense				
Profit after change in fair value				
of biological assets	127,724	125,965	362,949	264,198
Change in fair value of biological assets	(5,200)	(26,090)	(13,433)	(46,798)
Total tax expense	40,884	30,422	112,782	71,187
Profit excluding tax	163,408	130,297	462,298	288,587
Tax calculated using Malaysian tax rate of 24% (2021: 24%)				
- Prima facie income tax expense	39,218	31,271	110,951	69,261
- Non-deductible expenses	1,339	1,482	3,471	3,590
- Tax exempt income	(210)	-	(1,176)	-
- Movements in unrecognized deferred				
tax assets	1,239	(1,963)	238	(1,296)
- Over provision in prior years	(702)	(368)	(702)	(368)
Tax expense for the period	40,884	30,422	112,782	71,187

TA ANN HOLDINGS BERHAD

Notes to the interim financial report

22 Cash and Cash Equivalents

Cash and cash equivalents included in the statement of cash flows comprise the following amounts:

	As at 30 September 2022 RM'000	As at 30 September 2021 RM'000
Cash in hand	139	131
Cash at banks	512,794	307,802
Fixed deposits with original maturities not		
exceeding three months	87,006	55,538
	599,939	363,471
Other Investment	As at 30 September 2022 RM'000	As at 31 December 2021 RM'000
Fixed deposits with original maturities		
exceeding three months	1,061	1,050

24 Unquoted Investment and Properties

There were no sale of unquoted investments and properties during the financial quarter under review.

25 Quoted Investments

23

Total disposals of quoted securities for the financial period ended 30 September 2022 are as follows:

	RM'000
Sales consideration	9,129
Purchase consideration	(7,879)
Gain on disposal	1,250

26 Status of Corporate Proposal

There were no corporate proposals announced or pending completion as at the date of this announcement.

TA ANN HOLDINGS BERHAD

Notes to the interim financial report

27 Group Borrowings and Debt Securities

Total Group borrowings as at 30 September 2022 were as follows: -

		As at 30 September 2022 RM'000
Current		
Denominated in	Ringgit Malaysia	
Unsecured -	Bankers' acceptances/ Export credit refinancing	7,102
	Revolving credits Term loans	115,000
	- Islamic	23,520
Secured -	Hire purchase financing	5,277
	Revolving credits	26,000
	Term loans	30,631
		207,530
Non-current		
Denominated in	Ringgit Malaysia	
Unsecured -	Term loans	
	- Islamic	23,560
Secured -	Hire purchase financing	8,318
	Revolving credits	13,000
	Term loans	52,826
		97,704
Total		305,234

28 Material Litigation

There were no material litigations as at the date of this announcement.

TA ANN HOLDINGS BERHAD

Notes to the interim financial report

29 Significant Related Party Transactions

The Group entered into the following transactions with related parties, other than compensations to Directors and other key management personnel (see Note 30), during the current financial period:

	9 months ended 30 September	
	2022 RM'000	2021 RM'000
Transactions with associates	KIVI UUU	
	20.040	26.257
Purchase of fresh fruit bunches	30,048	36,257
Purchase of palm kernel shell	1,501	1,131
Sales of fresh fruit bunches	(975)	(1,233)
Sales of logs and timber products	(83)	(290)
Contract income	(592)	(491)
Transactions with companies connected to certain		
Directors of the Company and its subsidiaries		
Contract fees and fuel surcharge	13,816	14,275
Handling fees, transportation & freight charges	15,061	17,428
Insurance premium	3,268	2,849
Purchase of fresh fruit bunches	207,931	246,105
Rental of premises paid	5	14
Purchase of spare parts, fertiliser & consumables	9,664	7,470
Purchase of logs and timber products	3,078	2,035
Security charges	156	192
Computer hardware & software development fees	1,315	1,104
Purchase of diesel and lubricants	29,338	16,545
Purchase of palm kernel shell	1,519	2,035
Hire of property, plant and equipment	48	-
Sales of logs and timber products	(3,864)	(2,708)
Sales of fresh fruit bunches	(84,047)	(61,258)
Income from rental of premises	(59)	(59)
Handling fee received	(2,013)	(1,956)
Transport subsidised	(988)	(750)
*	======	======

30 Key Management Personnel Compensation

Compensations to key management personnel are as follows:

	9 months ended 30 September	
	2022	2021
	RM'000	RM'000
Directors		
- Fees	858	858
- Remunerations	3,667	4,468
	4,525	5,326
Other key management personnel		
- Fees	54	54
- Remunerations	2,155	1,909
	2,209	1,963
Total	6,734	7,289

•

....

1 1 20 0 4 1

TA ANN HOLDINGS BERHAD

Notes to the interim financial report

31 Earnings Per Share

(a)	Basic	3 months ended 30 September 2022	9 months ended 30 September 2022
	Net profit attributable to ordinary owners of the Company ('000)	<u>RM 101,495</u>	<u>RM 298,134</u>
	Weighted average number of ordinary shares in issue ('000)	<u>440,462</u>	<u>440,462</u>
	Basic earnings per ordinary share (sen)	<u>23.04</u>	<u>67.69</u>
(b)	Diluted	<u>23.04</u>	<u>67.69</u>

32 Gain/Losses arising from Fair Value Changes of Financial Liabilities

There were no gains or losses arising from fair value changes of financial liabilities for the current quarter ended 30 September 2022.

33 Authorisation for Issue

The interim financial statements were authorised for issue by the Board of Directors in accordance with a resolution of the Directors on 29 November 2022.